tbuckley/cabot-search huggingface dataset:
POISONING FROM OIL OF TANSY.
Authors: NELSON M. WHITEHILL
Journal: JAMA (1906)

The maximum dose of oil of tansy is given by most authorities as about eight minims. Considering the small size of the dose required and the frequency with which it is used by women as an emmenagogue and abortifacient, it is surprising that we do not more often hear of poisoning resulting therefrom. I have watched the literature closely for reports of cases of this kind, but have seen only one reported by Dr. Leipziger<sup>1</sup>of Burlington, Iowa. From druggists I learn that it has a reputation among the laity as an emmenagogue and that it is used frequently by women and girls who suspect and wish to avoid pregnancy. The two cases which have come to my notice are very similar, and one of them I wish to report. Both cases occurred in young, unmarried women who, not having menstruated as usual, suspected pregnancy. Later developments proved their
Single-Unit Sympathetic Discharge
Authors: John P. Greenwood, John B. Stoker, David A. S. G. Mary
Journal: Circulation (1999)

Background —Reports demonstrating sympathetic hyperactivity in hypertension with the use of microneurography have been inconsistent. One possible reason is that previous studies have assessed muscle sympathetic nerve activity (MSNA) from integrated voltage waves (“bursts”) recorded from multiunit discharges. We studied single units with defined vasoconstrictor properties (s-MSNA) to further characterize sympathetic output in hypertensive disease. Methods and Results —We examined 74 subjects with a wide range of arterial blood pressure that were considered to be either normal (NT), high normal (HN), or stages 1 to 3 essential hypertension (EHT-1, EHT-2/3). All had their peripheral sympathetic activity measured from both multiunit bursts and single-unit vasoconstrictor impulses. There was a significant correlation between s-MSNA and MSNA, and results of variability studies were similar. The EHT-1 and EHT-2/3 groups had greater s-MSNA and MSNA than did the matched NT group (always P &lt;0.01). The HN group also had greater s-MSNA and MSNA than did the NT group (mean±SEM; 43±5 vs 29±2 impulses/100 beats, P &lt;0.05; 36±4 vs 24±2 bursts/100 beats, P &lt;0.05). In addition, the EHT-1 group had significantly greater s-MSNA than did the EHT-2/3 group (63±6 vs 51±3 impulses/100 beats, P &lt;0.05), which could not be demonstrated with MSNA bursts. Conclusions —Quantification from single vasoconstrictor units has provided additional evidence in established essential hypertension of increased central sympathetic output. Furthermore, in the mild or early stages of hypertension, this technique has provided new evidence of augmented sympathetic output compared with more severe hypertension.
Calmodulin kinase II inhibition protects against structural heart disease
Authors: Rong Zhang, Michelle S C Khoo, Yuejin Wu, Yingbo Yang, Chad E Grueter, Gemin Ni, Edward E Price, William Thiel, Silvia Guatimosim, Long-Sheng Song, Ernest C Madu, Anisha N Shah, Tatiana A Vishnivetskaya, James B Atkinson, Vsevolod V Gurevich, Guy Salama, W J Lederer, Roger J Colbran, Mark E Anderson
Journal: Nature Medicine (2005)
Top coalition MPs have trained to be Dementia Friends, conference hears
Authors: N. Hawkes
Journal: BMJ (2014)

The cabinet table at 10 Downing Street has seen many historic moments, but it has never before been the venue for a course in becoming a “Dementia Friend.” 

The health secretary, Jeremy Hunt, told the independent think tank Reform’s annual conference in London on 2 December that, at that morning’s meeting, the entire cabinet had trained to join the Dementia Friends group—now 580 000 strong—which aims for a greater understanding of the condition and how to provide the small things that can make life easier for those who have it.

Ministers had been asked to guess how many steps are involved for a person with dementia to make a cup of tea. The answer, apparently, is 13 to 19, but Hunt did not say if any cabinet members got it right. The Dementia Friends scheme is part of the government’s focus on raising the profile …
Bacon Therapy and Furuncular Myiasis
Authors: Timothy F. Brewer
Journal: JAMA (1993)

To evaluate a simple, noninvasive method for removing fly larvae from patients with furuncular myiasis.Case series.Ambulatory office of a tertiary care center.Three patients who presented with Dermatobia hominis infestation.The patients with D hominis infestation were treated with the application of bacon fat over the larval apertures.Removal of intact larvae.Within 3 hours of the application of bacon, the larvae had migrated sufficiently far out of the skin to be removed with tweezers. Ten larvae were removed with this method. There were no treatment failures or complications.Furuncular myiasis will be seen more frequently in temperate areas as individuals travel to endemic areas. We describe the clinical characteristics of myiasis and a simple method of treatment that permits rapid diagnosis and cure.
Electron-beam therapy in scleredema adultorum with associated monoclonal hypergammaglobulinaemia
Authors: C. ANGELI-BESSON, M.C. KOEPPEL, P. JACQUET, L. ANDRAC, J. SAYAG
Journal: British Journal of Dermatology (1994)

Journal Article Electron‐beam therapy in scleredema adultorum with associated monoclonal hypergammaglobulinaemia Get access C. ANGELI‐BESSON, C. ANGELI‐BESSON Departments of Dermatology, CHU la Timone, Bd. Jean Moulin, 13385 Marseille, Cédex 05, France Search for other works by this author on: Oxford Academic Google Scholar M.C. KOEPPEL, M.C. KOEPPEL Departments of Dermatology, CHU la Timone, Bd. Jean Moulin, 13385 Marseille, Cédex 05, France Search for other works by this author on: Oxford Academic Google Scholar P. JACQUET, P. JACQUET Departments of Dermatology, CHU la Timone, Bd. Jean Moulin, 13385 Marseille, Cédex 05, France Search for other works by this author on: Oxford Academic Google Scholar L. ANDRAC, L. ANDRAC Departments of Anatomopathology, CHU la Timone, Bd. Jean Moulin, 13385 Marseille, Cédex 05, France Search for other works by this author on: Oxford Academic Google Scholar J. SAYAG J. SAYAG Departments of Dermatology, CHU la Timone, Bd. Jean Moulin, 13385 Marseille, Cédex 05, France Search for other works by this author on: Oxford Academic Google Scholar British Journal of Dermatology, Volume 130, Issue 3, 1 March 1994, Pages 394–397, https://doi.org/10.1111/j.1365-2133.1994.tb02940.x Published: 01 March 1994 Article history Accepted: 28 July 1993 Published: 01 March 1994
Expert Medical Testimony.
Authors: T. Ridgway Barker
Journal: JAMA (1896)

Philadelphia, Sept. 28, 1896. <h3>To the Editor:</h3> —There have been many papers and articles written on the subject of expert testimony but none I think so clearly express what is needed in courts as that published in ourJournalof Sept. 26, by L. Harrison Mettler of Chicago, under the title of "Insanity in Court." The Doctor's arguments are so convincing that criticism is well nigh disarmed. His demand for a separate medical trial to precede the civil where a plea of insanity is offered, carries great weight and would seem to be perfectly fair. The commission, suggested by him, to be composed of learned and experienced experts appointed by the supreme court or in other constitutional way beyond the reach of politics is certainly to be desired. It is only too true that "the present system does not carry out the abstract spirit of the law that every man
The Natural History of Medical Subspecialties
Authors: PAUL B. BEESON
Journal: Annals of Internal Medicine (1980)

Factors that have favored the division of the field of internal medicine into numerous subspecialties during the past three decades are reviewed. Some specialty areas are suited almost exclusively to academic clinical investigators, whereas others can be the basis for private practice. Some requisites for viability as a practice subspecialty are listed. It is suggested that in the coming decade the pendulum of preference is likely to swing back somewhat, with a larger fraction of young internists choosing to be identified as practicing general internal medicine rather than limiting their work to a single subspecialty.
Substance use seems to be increasing among 11 year olds
Authors: I. Sutherland
Journal: BMJ (2000)

EDITOR—Plant and Miller report that illicit drug use has declined since they carried out a survey in 1995.1 Their overall findings are broadly in agreement with similar work undertaken by Goddard and Higgins2 and by us. Goddard and Higgins reported that 7% of 11-15 year olds said that they had used illicit drugs within the past month and that prevalence increased sharply with age, …
Cantrell’s Syndrome: Left Ventricular Diverticulum in an Adult Patient
Authors: Edward G. Abinader, Dawod Sharif
Journal: Circulation (2001)

We read with interest the findings reported by Gruberg et al. 1 At 33 years of age, the patient had left ventricular hypertrophy by echocardiography and, in the absence of obvious reasons for hypertrophy, the diagnosis of hypertrophic cardiomyopathy (HCM) should be considered.The electrocardiographic changes and the spade-like appearance of the left ventricle at angiography (Figure 3) support the diagnosis of apical HCM.Furthermore, the authors report a normal ventriculogram at 33 years, thus excluding the diagnosis of a congenital defect and supporting acquired disease diagnosed 16 years later at the age of 49 years.We reported on a patient with apical HCM 2 who, at long-term follow-up, had attenuation of the amplitude of the R waves and reduced negativity of the giant precordial T waves associated with progressive development of apical left ventricular aneurysm and normal coronary angiogram.Thus, the findings reported by the authors favor the diagnosis of apical HCM with progressive remodelling of the left ventricular apex, rather than a congenital defect in the form of Cantrell's syndrome.
Subcutaneous Ossification of the Legs in Chronic Venous Insufficiency
Authors: Benjamin K. Fisher
Journal: JAMA (1961)

THIS PAPER draws attention to a newly described entity, which might be much more common than is suspected. The characteristic features have been aptly described by Lippmann1and Lippmann and Goldin.2This entity may be the underlying cause of a non-healing leg ulcer, and its diagnosis may help in the choice of a more satisfactory therapy.  Report of a Case  An obese 50-year-old Negro woman was first seen in the skin clinic of the Jackson Memorial Hospital, on Aug. 29, 1960. She complained of a small 2-by-3-cm. ulcer on the medial aspect of her left lower leg, which had been present for approximately 3 months. The leg was swollen. The diagnosis of stasis ulcer was made, and the patient treated with conservative measures: elastic pressure bandages and daily cleansing of the lesion with 3% hydrogen peroxide, followed by the application of a combination ointment containing neomycin, bacitracin,
Updated consensus statement on biological agents for the treatment of rheumatoid arthritis and other rheumatic diseases (May 2002)
Authors: D E Furst, F C Breedveld, J R Kalden, J S Smolen, C E Antoni, J W J Bijlsma, G R Burmester, B Cronstein, E C Keystone, A Kavanaugh, L Klareskog
Journal: Annals of the Rheumatic Diseases (2002)

A s in previous years, the consensus group to consider the use of biological agents was formed by an organising committee constituted of rheumatologists from the Universities of Erlangen, Leiden, and Vienna in Europe in cooperation with universities in the United States, Canada, and Europe. Pharmaceutical industry support was obtained from a number of companies, but these institutions had no part in the decisions about the specific programme or about the academic participants at this conference.

The 158 rheumatologists and bioscientists from 22 countries who attended the consensus conference were chosen from a worldwide group of people felt to have experience or interest in the use of biological agents for the treatment of rheumatoid arthritis (RA) and other rheumatic diseases. Unfortunately, the number of attendees and participants was limited so that not everyone who might have been appropriate could be invited.

Additional information has come to light in the past year, both corroborating the major positive effect these drugs have had in RA and documenting possible new and unexpected adverse events. In addition, the first of a new class of targeted biological agents, interleukin 1 (IL1) blocking agents, has become available. Therefore an update of the previous consensus statement1 seems both appropriate and necessary.

In the present update the consensus statement is annotated to document the credibility of the data supporting it as much as possible. This annotation is that of Shekelle et al and is described in appendix 3.2 All participants reviewed relevant clinical published articles relating to tumour necrosis factor (TNF) and IL1 blocking agents. They were given a draft consensus statement and were asked to revise the document in small discussion groups; open discussion of the revisions led to a final document, representing this updated consensus statement.

Individual patients differ in the aggressiveness of their …
Day 14 bone marrow biopsy in predicting complete remission and survival in acute myeloid leukemia
Authors: Kebede Hussein, Balkrishna Jahagirdar, Pankaj Gupta, Linda Burns, Karen Larsen, Daniel Weisdorf
Journal: American Journal of Hematology (2008)

Abstract We retrospectively analyzed 194 previously untreated acute myeloid leukemia (AML) patients to evaluate the role of Day 14 bone marrow (BM) biopsy in predicting complete remission (CR). Sixty‐seven percent received induction therapy. Achieving Day 14 BM ≤5% blasts was strongly predictive of Day 28 CR with 90% sensitivity and 79% positive predictive value; but weak 43% specificity and 29% negative predictive value. Day 14 BM biopsy is highly sensitive in predicting CR, but did not predict overall survival. Some patients with BM blast &gt;5% at Day 14 may still achieve a Day 28 CR, and not necessarily need reinduction therapy though high risk cytochemical or cytogenetic phenotype predicts a need for retreatment. Am. J. Hematol., 2008. © 2008 Wiley‐Liss, Inc.
Helping Patients Understand Risks: 7 Simple Strategies for Successful Communication
Authors: Domhnall MacAuley
Journal: BMJ (2006)

Hands up if you skipped epidemiology and statistics lectures when you were a student. Struggle with maths homework? Still think you have a realistic chance when you buy a lottery ticket? Many doctors are uncomfortable with numbers and, unless you are interested in horse racing, greyhounds, or cards, it is difficult to fully understand risk, chance, and the odds of success. But our patients want to know the likelihood of success in an operation, the benefits …
Dropout and Relapse During Diabetes Care
Authors: Alan L Graber, Patricia Davidson, Anne W Brown, John R McRae, Kathleen Woolridge
Journal: Diabetes Care (1992)

OBJECTIVE To determine factors associated with dropout and relapse during chronic diabetes care. RESEARCH DESIGN AND METHODS Private practice outpatient treatment-education program for adult diabetes was surveyed. Retrospective analysis was done, involving 422 patients for up to 3 yr. RESULTS Of the patients in the study, 12% dropped out after the initial visit, and 33% of the residual cohort dropped out during each subsequent 6-mo period. Factors associated with dropout included distance from home to clinic &amp;gt; 100 miles, lack of insulin treatment, and cigarette smoking. In patients who remained in follow-up, a significant decrease in HbA1C occurred during the first 6 mo, but 40% of the patients relapsed between 6 and 12 mo. Frequency of relapse declined as time passed. Relapse was more frequent in women. CONCLUSIONS Dropout from treatment and relapse after temporary improvement account for a substantial amount of uncontrolled diabetes, and overcoming the obstacles of dropout and relapse has potential for significant improvement in diabetes care.
Small-Molecule ONC201/TIC10 Targets Chemotherapy-Resistant Colorectal Cancer Stem–like Cells in an Akt/Foxo3a/TRAIL–Dependent Manner
Authors: Varun V. Prabhu, Joshua E. Allen, David T. Dicker, Wafik S. El-Deiry
Journal: Cancer Research (2015)

Abstract Self-renewing colorectal cancer stem/progenitor cells (CSC) contribute to tumor maintenance and resistance to therapy. Therapeutic targeting of CSCs could improve treatment response and prolong patient survival. ONC201/TIC10 is a first-in-class antitumor agent that induces TRAIL pathway–mediated cell death in cancer cells without observed toxicity. We have previously described that ONC201/TIC10 exposure leads to transcriptional induction of the TRAIL gene via transcription factor Foxo3a, which is activated by dual inactivation of Akt and ERK. The Akt and ERK pathways serve as important targets in CSCs. Foxo3a is a key mediator of Akt and ERK-mediated CSC regulation. We hypothesized that the potent antitumor effect of ONC201/TIC10 in colorectal cancer involves targeting CSCs and bulk tumor cells. ONC201/TIC10 depletes CD133+, CD44+, and Aldefluor+ cells in vitro and in vivo. TIC10 significantly inhibits colonosphere formation of unsorted and sorted 5-fluorouracil–resistant CSCs. ONC201/TIC10 significantly reduces CSC-initiated xenograft tumor growth in mice and prevents the passage of these tumors. ONC201/TIC10 treatment also decreased xenograft tumor initiation and was superior to 5-fluorouracil treatment. Thus, ONC201/TIC10 inhibits CSC self-renewal in vitro and in vivo. ONC201/TIC10 inhibits Akt and ERK, consequently activating Foxo3a and significantly induces cell surface TRAIL and DR5 expression in both CSCs and non-CSCs. ONC201/TIC10-mediated anti-CSC effect is significantly blocked by the TRAIL sequestering antibody RIK-2. Overexpression of Akt, DR5 knockdown, and Foxo3a knockdown rescues ONC201/TIC10-mediated depletion of CD44+ cells and colonosphere inhibition. In conclusion, ONC201/TIC10 is a promising agent for colorectal cancer therapy that targets both non-CSCs and CSCs in an Akt–Foxo3a–TRAIL–dependent manner. Cancer Res; 75(7); 1423–32. ©2015 AACR.
PET to assess early metabolic response and to guide treatment of adenocarcinoma of the oesophagogastric junction: the MUNICON phase II trial
Authors: Florian Lordick, Katja Ott, Bernd-Joachim Krause, Wolfgang A Weber, Karen Becker, Hubert J Stein, Sylvie Lorenzen, Tibor Schuster, Hinrich Wieder, Ken Herrmann, Rainer Bredenkamp, Heinz Höfler, Ulrich Fink, Christian Peschel, Markus Schwaiger, Jörg R Siewert
Journal: The Lancet Oncology (2007)
Pets in the home and the development of pet allergy in adulthood. The Copenhagen Allergy Study
Authors: A. Linneberg, N. H. Nielsen, F. Madsen, L. Frølund, A. Dirksen, T. Jørgensen
Journal: Allergy (2003)

Background: The aim of the study was to investigate the association between exposure to cat and dog in the home and the development (incidence) of IgE sensitization to cat and dog. Methods: Participants in a population‐based study of 15–69‐year‐olds in 1990 were invited to a follow‐up in 1998. Serum IgE antibodies against common inhalant allergens was assessed in 734 subjects (participation rate 69.0%) on two occasions 8 years apart. Information about current or previous keeping of cats and dogs in the home was obtained in a questionnaire at baseline. Results: A cat in the home currently was significantly associated with the development of IgE sentisization to cat (adjusted odds ratio 8.4, 95% confidence interval (CI) 1.7–42.7). Moreover, an atopic predisposition in terms of IgE sensitization to allergens other than cat at baseline was an independent risk factor for the development of IgE sensitization to cat. A dog in the home was not significantly associated with the development of IgE sensitization to dog. Conclusions: In this adult population, exposure to a cat in the home increased the risk of developing IgE sensitization to cat. More prospective data are needed on this issue.
US Military Medicine Responds to Results of Terrorism in Africa
Authors: Phil Gunby
Journal: JAMA (1998)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Moesin and CD44 expression in cutaneous melanocytic tumours
Authors: None Ichikawa, None Masumoto, None Kaneko, None Saida, None Sagara, None Taniguchi
Journal: British Journal of Dermatology (1998)

Journal Article Moesin and CD44 expression in cutaneous melanocytic tumours Get access T. Ichikawa, T. Ichikawa Departments of Dermatology, Search for other works by this author on: Oxford Academic Google Scholar J. Masumoto, J. Masumoto Molecular Oncology and Angiology, Angio‐Ageing Research Division, Research Centre on Ageing and Adaptation, Shinshu University School of Medicine, Asahi 3‐1‐1, Matsumoto 390, Japan Search for other works by this author on: Oxford Academic Google Scholar M. Kaneko, M. Kaneko Departments of Dermatology, Search for other works by this author on: Oxford Academic Google Scholar T. Saida, T. Saida Departments of Dermatology, Search for other works by this author on: Oxford Academic Google Scholar J. Sagara, J. Sagara Molecular Oncology and Angiology, Angio‐Ageing Research Division, Research Centre on Ageing and Adaptation, Shinshu University School of Medicine, Asahi 3‐1‐1, Matsumoto 390, Japan Search for other works by this author on: Oxford Academic Google Scholar S. Taniguchi S. Taniguchi Molecular Oncology and Angiology, Angio‐Ageing Research Division, Research Centre on Ageing and Adaptation, Shinshu University School of Medicine, Asahi 3‐1‐1, Matsumoto 390, Japan Taniguchi Molecular Oncology and Angiology, Angio‐Ageing Research Division, Research Centre on Ageing and Adaptation, Shinshu University School of Medicine, Asahi 3‐1‐1, Matsumoto 390, Japan Search for other works by this author on: Oxford Academic Google Scholar British Journal of Dermatology, Volume 138, Issue 5, 1 May 1998, Pages 763–768, https://doi.org/10.1046/j.1365-2133.1998.02255.x Published: 01 May 1998
The MLL partial tandem duplication in adults aged 60 years and older with de novo cytogenetically normal acute myeloid leukemia
Authors: S P Whitman, M A Caligiuri, K Maharry, M D Radmacher, J Kohlschmidt, H Becker, K Mrózek, Y-Z Wu, S Schwind, K H Metzeler, J H Mendler, J Wen, M R Baer, B L Powell, T H Carter, J E Kolitz, M Wetzler, A J Carroll, R A Larson, G Marcucci, C D Bloomfield
Journal: Leukemia (2012)